Acute Respiratory Distress Syndrome
Conditions
Keywords
Acute Respiratory Distress Syndrome, Sedation, Sevoflurane, Propofol, Volatile anesthetics, Intravenous anesthetics, Inhalational anesthetics, Intensive care unit
Brief summary
The American European Consensus Conference (AECC) 1994 defined acute respiratory distress syndrome (ARDS) as an acute inflammatory syndrome manifesting as diffuse pulmonary edema and respiratory failure that cannot be explained by, but may co-exist with, left-sided heart failure. During the sequel Conference of the European Society of Intensive Care Medicine, in 2012 minor changes were made, and since that so-called Berlin definition of ARDS is used worldwide for the description of this severe disease. Three grades of severity were proposed to distinguish ARDS according to the level of hypoxemia with a mortality of 24% in patients with mild ARDS, rising to 48% in those with severe ones. Systemic inflammation is considered to be the main reason of ARDS. Activated neutrophils interact with the alveolar-capillary membrane causing the increasing permeability with the sequence lung edema's development. Inflammatory exudate inactivates surfactant leading to collapse and consolidation of distal airspaces with progressive loss of the lung's gas exchange surface area. Unfortunately, systemic inflammatory response syndrome (SIRS) simultaneously inhibits the mechanism of active pulmonary vasoconstriction and allows deoxygenated blood to pass through unventilated areas of the lung boosting the right-to-left shunt. Both mechanisms lead to hypoxemia, which is the main and obligatory feature of ARDS. Actually, endothelial dysfunction and transcapillary leakage seem to be one of the main steps in the development of respiratory failure during ARDS. Last decades it was found out that glycocalyx is also participating in this process too. Thus, it became clear that substances preserving endothelium and glycocalyx from SIRS-causing damage may have a beneficial effect in ARDS treatment. It seems to be crucially important so as the majority of drugs failed to demonstrate any positive effects in terms of ARDS treatment. To the moment we have some evidence, which came from experimental studies, that halogenated anesthetics can preserve glycocalyx against ischemia-reperfusion injury. The primary objective for the multicentral INVERSE Trial will be to determine the effects of inhalational (sevoflurane) versus intravenous (propofol) sedation on P/F ratio on the second day, hospital mortality and ICU (intensive care unit), and in-hospital length of stay in adults with a moderate form of ARDS.
Interventions
DRUGSevoflurane
Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
DRUGPropofol
Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
Sponsors
Negovsky Reanimatology Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 * Endotracheal intubation or tracheostomy * Timing: Acute onset of new or worsening of chronic respiratory symptoms within 72 hours before the randomization * Chest imaging: Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules * Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload * Oxygenation: 100 mm Hg \< PaO2/FiO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O
Exclusion criteria
* History or family history of malignant hyperthermia * History of propofol infusion syndrome * Documented or suspected increased intracranial pressure * Chronic restrictive pulmonary disease * Chronic obstructive pulmonary disease * Neuromuscular disease * Chest wall disorder * Pulmonary vascular disease * NYHA class ≥ 3 * Severe pulmonary hypertension (mean pulmonary artery pressure \> 40 mmHg) * Documented ongoing COVID-19 infection * Ongoing immunosuppressive therapy * Previous randomization in this trial * Post randomization exclusion criterion: Documented ongoing COVID-19 infection during the first 48 hours after the randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| P/F ratio | day 2 after the randomization | PaO2 divided on FiO2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-months mortality | 6 months | number of deaths |
| 1-year mortality | 1 year | number of death |
| Length of stay in the intensive care unit | 1 year | number of days in the intensive care unit |
| 28-days mortality | 28 day | number of deaths |
| Ventilator free days in ICU | 1 year | number of days in ICU - number of days on mechanical ventilation |
| Ventilator free days during hospitalization | 1 year | Length of hospitalization - number of days on mechanical ventilation |
| Length of hospitalization | 1 year | number of days in hospital |
Countries
Russia
Outcome results
None listed